Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The association of body mass index with tumor aggression among men undergoing radical prostatectomy.
Gregg JR, Magill R, Fang AM, Chapin BF, Davis JW, Adibi M, Chéry L, Papadopoulos J, Pettaway C, Pisters L, Ward JF, Hahn AW, Daniel CR, Bhaskaran J, Zhu K, Guerrero M, Zhang M, Troncoso P. Gregg JR, et al. Among authors: hahn aw. Urol Oncol. 2024 Apr;42(4):116.e1-116.e7. doi: 10.1016/j.urolonc.2023.12.013. Epub 2024 Jan 22. Urol Oncol. 2024. PMID: 38262868
Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones.
Sakellakis MJ, Hahn AW, Ramachandran S, Zhang M, Hoang A, Song JH, Liu J, Wang F, Basu HS, Sheperd P, Wang X, Frigo DE, Lin SH, Panaretakis T, Zhang J, Navone N, Troncoso P, Logothetis CJ, Titus MA. Sakellakis MJ, et al. Among authors: hahn aw. Prostate Cancer Prostatic Dis. 2023 Dec;26(4):751-758. doi: 10.1038/s41391-022-00590-x. Epub 2022 Sep 13. Prostate Cancer Prostatic Dis. 2023. PMID: 36100698
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.
Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Vashisht Gopal YN, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JL. Hahn AW, et al. Clin Cancer Res. 2023 Jan 4;29(1):154-164. doi: 10.1158/1078-0432.CCR-22-2661. Clin Cancer Res. 2023. PMID: 36166093 Free PMC article.
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.
Aparicio AM, Tidwell RSS, Yadav SS, Chen JS, Zhang M, Liu J, Guo S, Pilié PG, Yu Y, Song X, Vundavilli H, Jindal S, Zhu K, Viscuse PV, Lebenthal JM, Hahn AW, Soundararajan R, Corn PG, Zurita-Saavedra A, Subudhi SK, Zhang J, Wang W, Huff C, Troncoso P, Allison JP, Sharma P, Logothetis CJ. Aparicio AM, et al. Among authors: hahn aw. Clin Cancer Res. 2024 Jul 1;30(13):2751-2763. doi: 10.1158/1078-0432.CCR-23-3740. Clin Cancer Res. 2024. PMID: 38683200 Free PMC article. Clinical Trial.
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates.
Hahn AW, Manyam GC, Chapin BF, Zhang M, Yu Y, Pettaway CA, Chery L, Pisters LL, Ward JF, Gregg JR, Papadopoulos J, Kamat AM, Lozano M, Hoang A, Broom B, Wang X, Huff CD, Logothetis CJ, Troncoso P, Pilié PG, Davis JW. Hahn AW, et al. BJU Int. 2024 Sep;134(3):449-458. doi: 10.1111/bju.16414. Epub 2024 Jun 4. BJU Int. 2024. PMID: 38837608 Clinical Trial.
Body composition as a determinant of the therapeutic index with androgen signaling inhibition.
Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Hahn AW, et al. Prostate Cancer Prostatic Dis. 2024 Jul 17. doi: 10.1038/s41391-024-00870-8. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39019979
Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer.
Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N. Swami U, et al. Among authors: hahn aw. Eur Urol. 2020 Nov;78(5):652-656. doi: 10.1016/j.eururo.2020.06.033. Epub 2020 Jul 2. Eur Urol. 2020. PMID: 32624276 Free PMC article.
External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer.
Swami U, Sayegh N, Jo Y, Haaland B, McFarland TR, Nussenzveig RH, Goel D, Sirohi D, Hahn AW, Maughan BL, Goldkorn A, Agarwal N. Swami U, et al. Among authors: hahn aw. Mol Cancer Ther. 2022 Dec 2;21(12):1857-1861. doi: 10.1158/1535-7163.MCT-22-0020. Mol Cancer Ther. 2022. PMID: 36198026 Clinical Trial.
280 results